Sakoda Lori C, Blackston Christie R, Xue Kan, Doherty Jennifer A, Ray Roberta M, Lin Ming Gang, Stalsberg Helge, Gao Dao Li, Feng Ziding, Thomas David B, Chen Chu
Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Department of Epidemiology, University of Washington, Mailstop M4-C308, P.O. Box 19024, Seattle, WA 98109-1024, USA.
Breast Cancer Res Treat. 2008 May;109(1):143-55. doi: 10.1007/s10549-007-9633-5. Epub 2007 Jul 12.
Enzymes encoded by the glutathione S-tranferase mu 1 (GSTM1) and pi 1 (GSTP1) genes, which are expressed in breast tissue, catalyze the detoxification of endogenous and exogenous electrophiles. Reduced enzyme activity, due to carriage of the GSTM1 deletion or the GSTP1 Ile105Val Val allele, may therefore affect susceptibility to breast cancer and related conditions. In a case-control study of Chinese women, we examined whether these polymorphisms were associated with risk of breast cancer and fibrocystic breast conditions. Women diagnosed with breast cancer (n=615) or fibrocystic breast conditions (n=467) were compared to women without clinical breast disease (n=878). We also examined whether these associations differed by menopausal status or by presence of proliferation in the extra-tumoral epithelium among women with breast cancer and in lesions among women with fibrocystic conditions. No overall association of either GST polymorphism with risk of breast cancer or fibrocystic breast conditions was observed. There was some evidence of slightly elevated cancer risk associated with carriage of the GSTM1 null genotype and at least one GSTP1 105-Val allele (OR=1.33, 95% CI, 0.99-1.80), compared to carriage of the GSTM1 non-null and GSTP1 Ile/Ile genotypes. This relationship was stronger in women who had breast cancer with extra-tumoral tissue proliferation (OR=1.77, 95% CI, 1.03-3.04). Our results suggest that GSTM1 and GSTP1 genotypes do not individually influence susceptibility to breast cancer or fibrocystic breast conditions. The observed increased risk of breast cancer associated with joint carriage of the GSTM1 null genotype and GSTP1 105-Val allele needs confirmation in other studies.
谷胱甘肽S-转移酶μ1(GSTM1)和π1(GSTP1)基因编码的酶在乳腺组织中表达,可催化内源性和外源性亲电试剂的解毒。由于携带GSTM1缺失或GSTP1 Ile105Val Val等位基因导致酶活性降低,因此可能影响患乳腺癌及相关病症的易感性。在一项针对中国女性的病例对照研究中,我们研究了这些多态性是否与乳腺癌和乳腺纤维囊性病变的风险相关。将诊断为乳腺癌的女性(n = 615)或乳腺纤维囊性病变的女性(n = 467)与无临床乳腺疾病的女性(n = 878)进行比较。我们还研究了这些关联在绝经状态方面是否存在差异,或者在患有乳腺癌的女性肿瘤外上皮细胞增殖情况以及患有乳腺纤维囊性病变的女性病变情况方面是否存在差异。未观察到GST多态性与乳腺癌或乳腺纤维囊性病变风险之间存在总体关联。与携带GSTM1非缺失和GSTP1 Ile/Ile基因型相比,有一些证据表明携带GSTM1无效基因型和至少一个GSTP1 105-Val等位基因与癌症风险略有升高相关(OR = 1.33,95% CI,0.99 - 1.80)。这种关系在患有肿瘤外组织增殖的乳腺癌女性中更强(OR = 1.77,95% CI,1.03 - 3.04)。我们的结果表明,GSTM1和GSTP1基因型不会单独影响患乳腺癌或乳腺纤维囊性病变的易感性。观察到的与GSTM1无效基因型和GSTP1 105-Val等位基因共同携带相关的乳腺癌风险增加需要在其他研究中得到证实。